BioCryst Pharmaceuticals, Inc.

BMV:BCRX * Stock Report

Market Cap: Mex$31.8b

BioCryst Pharmaceuticals Valuation

Is BCRX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BCRX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BCRX * (MX$155) is trading below our estimate of fair value (MX$914.98)

Significantly Below Fair Value: BCRX * is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCRX *?

Key metric: As BCRX * is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BCRX *. This is calculated by dividing BCRX *'s market cap by their current revenue.
What is BCRX *'s PS Ratio?
PS Ratio3.8x
SalesUS$412.58m
Market CapUS$1.58b

Price to Sales Ratio vs Peers

How does BCRX *'s PS Ratio compare to its peers?

The above table shows the PS ratio for BCRX * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.6x
LAB B Genomma Lab Internacional. de
1.4x9.9%Mex$25.3b
NRIX Nurix Therapeutics
26.8x39.1%US$1.5b
A214450 PharmaResearch
6.9x24.2%₩2.2t
688276 Changchun BCHT Biotechnology
7.1x26.9%CN¥11.4b
BCRX * BioCryst Pharmaceuticals
3.8x15.3%Mex$1.6b

Price-To-Sales vs Peers: BCRX * is good value based on its Price-To-Sales Ratio (3.8x) compared to the peer average (10.6x).


Price to Sales Ratio vs Industry

How does BCRX *'s PS Ratio compare vs other companies in the Global Biotechs Industry?

272 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.n/a0%
BCRX * BioCryst Pharmaceuticals
3.8x15.3%US$1.58b
No. of Companies271PS01632486480+
272 CompaniesEstimated GrowthMarket Cap
Industry Avg.n/a0%
BCRX * BioCryst Pharmaceuticals
3.8x72.8%US$1.58b
No more companies

Price-To-Sales vs Industry: BCRX * is good value based on its Price-To-Sales Ratio (3.8x) compared to the Global Biotechs industry average (9.3x).


Price to Sales Ratio vs Fair Ratio

What is BCRX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCRX * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BCRX *'s Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BCRX * forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
Mex$299.49
0%
43.2%Mex$606.32Mex$161.69n/a11
Dec ’25n/a
Mex$294.41
0%
43.3%Mex$603.45Mex$160.92n/a11
Nov ’25n/a
Mex$280.77
0%
44.0%Mex$582.73Mex$135.97n/a11
Oct ’25n/a
Mex$280.62
0%
44.0%Mex$582.42Mex$135.90n/a11
Sep ’25Mex$170.00
Mex$280.62
+65.1%
44.0%Mex$582.42Mex$135.90n/a11
Aug ’25n/a
Mex$249.03
0%
46.7%Mex$533.64Mex$106.73n/a11
Jul ’25n/a
Mex$236.31
0%
46.7%Mex$506.39Mex$101.28n/a11
Jun ’25n/a
Mex$236.31
0%
46.7%Mex$506.39Mex$101.28n/a11
May ’25n/a
Mex$232.60
0%
46.7%Mex$505.00Mex$101.00n/a11
Apr ’25n/a
Mex$232.60
0%
46.7%Mex$505.00Mex$101.00n/a11
Mar ’25Mex$98.86
Mex$237.35
+140.1%
46.7%Mex$515.30Mex$103.06n/a11
Feb ’25n/a
Mex$237.35
0%
46.7%Mex$515.30Mex$103.06n/a11
Jan ’25n/a
Mex$241.06
0%
46.2%Mex$513.23Mex$102.65n/a11
Dec ’24n/a
Mex$241.06
0%
46.2%Mex$513.23Mex$102.65n/a11
Nov ’24n/a
Mex$274.41
0%
46.2%Mex$541.61Mex$144.43n/a10
Oct ’24n/a
Mex$260.32
0%
46.2%Mex$513.78Mex$137.01n/a10
Sep ’24n/a
Mex$258.14
0%
47.1%Mex$512.86Mex$136.76Mex$170.0010
Aug ’24n/a
Mex$258.02
0%
48.1%Mex$514.32Mex$137.15n/a10
Jul ’24Mex$120.00
Mex$259.38
+116.2%
47.2%Mex$513.62Mex$136.97n/a10
Jun ’24n/a
Mex$265.88
0%
45.8%Mex$533.38Mex$142.23n/a11
May ’24n/a
Mex$268.01
0%
45.5%Mex$539.29Mex$143.81n/a11
Apr ’24n/a
Mex$283.83
0%
41.7%Mex$550.97Mex$146.92n/a11
Mar ’24n/a
Mex$283.83
0%
41.7%Mex$550.97Mex$146.92Mex$98.8611
Feb ’24n/a
Mex$322.95
0%
36.2%Mex$580.16Mex$193.39n/a10
Jan ’24n/a
Mex$331.91
0%
35.6%Mex$592.70Mex$197.57n/a10
Dec ’23n/a
Mex$346.41
0%
31.8%Mex$590.47Mex$236.19n/a10

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies